This Biotech Fund Sold $8 Million, Yet Remains Bullish on Terns
A biotech fund reduced its Terns Pharmaceuticals position by about $8 million last quarter. Despite the sale, the the...
Risk parity assigns capital to balance risk contributions across asset classes in retirement portfolios, aiming for steadier, more resilient returns.
26,821 articlesA biotech fund reduced its Terns Pharmaceuticals position by about $8 million last quarter. Despite the sale, the the...
Investors are weighing whether HOOD deserves a place in a modern portfolio. This guide helps you gauge signals, risks...
A notable stake reduction by pacific ridge capital trims its NWPX position, signaling a shift in exposure. This guide...
Two very different paths define the nuclear renaissance: NuScale's small modular reactors and BWX Technologies' broad...
A single stake in HOPE Bancorp is signaling more than a stock pick—it's a case study in how bank consolidation can re...
Cloud giants are expanding, yet the super micro computer stock slid on a capital-raise plan. This article breaks down...
Two heavyweight tech stocks have surged on AI bets, but investors face a stark choice: own NVIDIA stock or Micron sto...
AST SpaceMobile just completed a trio of successful BlueBird launches, yet spacemobile's stock down after the event. ...
Geopolitical moves from the July U.S. strike on Iran sent shockwaves through crypto markets as Bitcoin and Ethereum p...
When a biotech deal moves a small cap, it can set the tone for the whole sector. This story explains what happened wi...
Investors ask if Apple stock should be bought before April 30. This guide offers a clear framework, real-world exampl...
First Solar has been delivering profits, but a heavy reliance on subsidies creates real investment risk. This article...